Summitry LLC’s GSK GSK Stock Holding History

Summitry LLC’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-51,430	Closed	-$2.37M	–	90
2020 Q4	$2.37M	Buy	51,430 +1,956	+4%	+$89.8K	0.17%	52
2020 Q3	$2.33M	Buy	49,474 +520	+1%	+$26.1K	0.19%	54
2020 Q2	$2.5M	Buy	48,954 +4,109	+9%	+$211K	0.21%	52
2020 Q1	$2.12M	Buy	44,845 +1,851	+4%	+$98.7K	0.19%	48
2019 Q4	$2.52M	Buy	42,994 +3,356	+8%	+$187K	0.2%	45
2019 Q3	$2.12M	Buy	39,638 +2,360	+6%	+$121K	0.17%	52
2019 Q2	$1.86M	Buy	37,278 +844	+2%	+$42.4K	0.15%	53
2019 Q1	$1.9M	Buy	36,434 +2,980	+9%	+$149K	0.17%	49
2018 Q4	$1.6M	Buy	33,454 +5,378	+19%	+$265K	0.16%	45
2018 Q3	$1.41M	Buy	28,076 +843	+3%	+$42.8K	0.12%	55
2018 Q2	$1.37M	Buy	27,233 +2,185	+9%	+$110K	0.13%	53
2018 Q1	$1.22M	Buy	25,048 +3,048	+14%	+$142K	0.11%	56
2017 Q4	$975K	Buy	22,000 +2,752	+14%	+$127K	0.09%	57
2017 Q3	$977K	Buy	19,248 +3,224	+20%	+$164K	0.09%	57
2017 Q2	$864K	Buy	16,024 +1,316	+9%	+$70.2K	0.08%	57
2017 Q1	$775K	Buy	14,708 +764	+5%	+$38.8K	0.07%	58
2016 Q4	$671K	Buy	13,944 +1,020	+8%	+$50.4K	0.07%	59
2016 Q3	$697K	Buy	12,924 +1,420	+12%	+$77.9K	0.07%	58
2016 Q2	$623K	Buy	11,504 +4,544	+65%	+$239K	0.06%	59
2016 Q1	$353K	Buy	6,960 +1,772	+34%	+$88.3K	0.04%	68
2015 Q4	$262K	Buy	+5,188	New	+$264K	0.03%	70

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return

Summitry LLC's GSK Position: Q1 2021 in Review

Summitry LLC sold out of GSK (GSK) in Q1 2021, closing a stake of 51,430 shares — an estimated $2.37M sold.

Summitry LLC first reported a position in GSK in Q4 2015 and held it in 21 quarters. The position peaked at $2.52M in Q4 2019. 776 funds tracked by Wall St. Rank hold GSK as of Q1 2021.

Summitry LLC reported no remaining GSK position as of Q1 2021 after selling out during the quarter.
Summitry LLC sold 51,430 GSK shares in Q1 2021, an estimated $2.37M.
Summitry LLC first reported a position in GSK in Q4 2015 and held it in 21 quarters.
Summitry LLC's GSK position peaked at $2.52M in Q4 2019.
776 funds tracked by Wall St. Rank held GSK as of Q1 2021.

Based on Summitry LLC's 13F filing for Q1 2021, filed 12 May 2021.